BioSpace News Archive

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report fourth quarter 2021 financial results after the close of the U.S. financial markets on Thursday, February 17, 2022 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.

Xeris Biopharma to Participate in the 11th Annual SVB Leerink Global Healthcare Conference.

Silence Therapeutics today announced positive topline results in its phase 1 single-ascending dose study of SLN360, an siRNA targeting lipoprotein(a) (“Lp(a)”), in healthy adults with high Lp(a).

STAAR Surgical Company today announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2021 on Wednesday, February 23, 2022 after the market close.

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today reported interim data from a collaborator-sponsored, ongoing Phase 1/2 clinical trial of AVR-RD-04.

Bristol Myers Squibb (NYSE:BMY) today announced that it has entered into accelerated share repurchase (ASR) transactions under agreements with Morgan Stanley & Co. LLC, Barclays Bank PLC, Citibank, N.A. and JPMorgan Chase Bank, N.A., (collectively, the “ASR Agreements”) to repurchase, in aggregate, $5 billion of Bristol Myers Squibb common stock.

Aptinyx Inc. will host a virtual portfolio review event today beginning at 10:00 a.m. ET. Presented in a live webcast format, the company will discuss its approach to the development of novel NMDA receptor modulators.

Nephros, Inc. today announced that it will file its fourth quarter financial results on Wednesday, February 23, 2022 after market close and will host a conference call that same day at 4:30 PM ET.

Humacyte, Inc. today announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, and Dale Sander, Chief Financial Officer, will participate in a virtual fireside chat at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Feb. 15, 2022, at 9 a.m. EST.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2021.